Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
New England Journal of Medicine · 25.01.2024 · 390 (4) · 326-337
DOI: 10.1056/nejmoa2310063 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 25.01.2024. Verfasst von Talha Munir und 32 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Clinical Hematology (T.M., P.H.) and the Hematological Malignancy Diagnostic Service (N.W., S.D., R.T., A.R.), Leeds Cancer Ce…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Vidarabine. Die Arbeit wurde bisher 179-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Cancer Research UK, Janssen Pharmaceutica NV, AbbVie Ltd..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Clinical Hematology (T.M., P.H.) and the Hematological Malignancy Diagnostic Service (N.W., S.D., R.T., A.R.), Leeds Cancer Centre, and the Leeds Cancer Research UK Clinical Trials Unit (D.A.C., D…
ORCID-Profile: Lelia Duley
Förderung
- Cancer Research UK
- Janssen Pharmaceutica NV
- AbbVie Ltd.
Zitieren
APA
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., …, & National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/nejmoa2310063
Vancouver
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. 2024;390(4):326-337. doi:10.1056/nejmoa2310063
BibTeX
@article{Munir2024,
author = {Munir, Talha and Cairns, David A and Bloor, Adrian and Allsup, David and Cwynarski, Kate and Pettitt, Andrew and Paneesha, Shankara and Fox, Christopher P and Eyre, Toby A and Forconi, Francesco and Elmusharaf, Nagah and Kennedy, Ben and Gribben, John and Pemberton, Nicholas and Sheehy, Oonagh and Preston, Gavin and Schuh, Anna and Walewska, Renata and Duley, Lelia and Howard, Dena and Hockaday, Anna and Jackson, Sharon and Greatorex, Natasha and Girvan, Sean and Bell, Sue and Brown, Julia M and Webster, Nichola and Dalal, Surita and de Tute, Ruth and Rawstron, Andrew and Patten, Piers E M and Hillmen, Peter and National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup, National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup},
title = {Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease},
journal = {New England Journal of Medicine},
year = {2024},
volume = {390},
number = {4},
pages = {326--337},
doi = {10.1056/nejmoa2310063}
}
EUVIMED